What happens when an entire biotech company is powered by AI?

Researchers at Stanford have built a virtual biotech involving around 37,000 AI agents , each designed to perform specialized roles across the drug-development process. In this episode of TechAsItIs , Ursula Paul explores how these AI agents analyzed around 50,000 clinical trials in less than a week , investigated biological targets, and proposed a potential cancer drug strategy.

But this isn't simply a story about AI replacing scientists. What happens when software can analyze thousands of possibilities, coordinate complex scientific tasks, and pursue a research goal through multiple specialized agents?

We break down how the system works, what it actually discovered, what it cannot prove, and why the most important part of the story may not be the number 37,000 — but the architecture behind it. Because the future of AI may not just be about systems that answer questions.

It may be about systems that work toward complex goals. Welcome to TechAsItIs — understanding the technology shaping our world.